You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK (GenomeWeb) – New data from a small prospective study has added to growing evidence that there is clinical value in monitoring patients with colorectal cancer using liquid biopsy, or circulating tumor DNA tests.
Premium Access gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.
Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.